Evolving role of positron emission tomography (PET) in urological malignancy.

about

Evolving role of positron emission tomography (PET) in urological malignancy.

Item

http://www.wikidata.org/entity/Q38269763

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh

2014年學術文章

@zh-hant

name

Evolving role of positron emission tomography (PET) in urological malignancy.

@en

type

Item

label

Evolving role of positron emission tomography (PET) in urological malignancy.

@en

prefLabel

Evolving role of positron emission tomography (PET) in urological malignancy.

@en

P1476

Evolving role of positron emission tomography (PET) in urological malignancy.

@en

P2093

Amit Patel

http://www.w3.org/2001/XMLSchema#string

Andrew C Thorpe

http://www.w3.org/2001/XMLSchema#string

Gregory Boustead

http://www.w3.org/2001/XMLSchema#string

James M Adshead

http://www.w3.org/2001/XMLSchema#string

Nikhil Vasdev

http://www.w3.org/2001/XMLSchema#string

Philip Haslam

http://www.w3.org/2001/XMLSchema#string

Sebastian Mafeld

http://www.w3.org/2001/XMLSchema#string

Tamir Ali

http://www.w3.org/2001/XMLSchema#string

Timothy Lane

http://www.w3.org/2001/XMLSchema#string

P2860

Update on positron emission tomography for imaging of prostate cancer

Regulation of choline kinase activity by Ras proteins involves Ral-GDS and PI3K

Overexpression of choline kinase is a frequent feature in human tumor-derived cell lines and in lung, prostate, and colorectal human cancers

Targeted therapies in renal cell cancer: recent developments in imaging

Clinical value of fluorine-18 2-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in bladder cancer.

Targeted therapies for the treatment of metastatic renal cell carcinoma: clinical evidence.

Pharmacodynamic study using FLT PET/CT in patients with renal cell cancer and other solid malignancies treated with sunitinib malate.

18F-FDG-PET/CT Imaging as an early survival predictor in patients with primary high-grade soft tissue sarcomas undergoing neoadjuvant therapy.

Sarcoma mid-therapy [F-18]fluorodeoxyglucose positron emission tomography (FDG PET) and patient outcome

Molecular imaging of urogenital diseases.

P304

538-545

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/BJU.12988

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

116

http://www.w3.org/2001/XMLSchema#string

P577

2014-11-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25410715

http://www.w3.org/2001/XMLSchema#string